About: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 1987

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 1987 (uk) im Juni 1987 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 1987 (ast) scientific article published on 01 June 1987 (en)
publication date	wds:Q68156084-B13FFAEC-F2F3-4857-8EDC-1140AC8586D3
publication date	1987-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q68156084-7E7BFACB-3E7E-45A2-AA85-03D2D7857488
language of work or name	English
author name string	wds:Q68156084-0E1BB983-FB55-4825-BAA2-2A04C7E0AA70 wds:Q68156084-3BBB5318-9924-47C4-AA7F-E57E56FA74D4 wds:Q68156084-64592D82-EAF2-4292-8ADA-152E8C99B156 wds:Q68156084-901BB6AA-59E5-4998-A650-8E2DAEE64EDF wds:Q68156084-C45AAFDA-62D0-4707-8B9C-3147083BA21B wds:Q68156084-D7438DF2-55DF-4BB1-85DD-F27F853A620C
author name string	R L Johnson D H Blankenhorn L Cashin-Hemphill S P Azen M E Sanmarco S A Nessim
rdfs:label	Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts (en) Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts (nl)
skos:prefLabel	Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts (en) Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts (nl)
name	Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts (en) Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts (nl)
title	wds:Q68156084-593A3255-4C7C-4667-BDC2-FFE6625363ED
title	Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts (en)
page(s)	wds:Q68156084-4DD0DCD4-156A-4279-8EBF-04BDA235F3F1
page(s)	3233-3240
instance of	wds:Q68156084-9EDA97E3-BB00-40C0-9CB0-E8520B2657F4
instance of	scholarly article
main subject	wds:Q68156084-CCD1BC62-D085-4898-8C21-77075B3069A9
main subject	coronary artery disease
PubMed ID	wds:Q68156084-18BEDF29-7E7D-4B9C-B846-8AFD0950C73D
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/3295315
PubMed ID	3295315
published in	wds:Q68156084-62C282D6-2FDD-4E96-9018-1FCA204D69C9
published in	The Journal of the American Medical Association
issue	wds:Q68156084-8301DC81-A08E-46AA-AB21-FF2E18B9E150
volume	wds:Q68156084-7A056C6B-7354-40D2-B46F-A67A941C5575
issue	23
volume	257
DOI	wds:Q68156084-2ABDFEE7-DBD0-46AF-A40F-0BF423C9C9E7
DOI	http://dx.doi.org/10.1001/JAMA.257.23.3233
DOI	10.1001/JAMA.257.23.3233
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q68156084
is cites work of	Cholesterol in patients with coronary heart disease: how low should we go? Preventive medicine and public health: cholesterol reduction-pros and cons Coronary Disease and Stroke in Patients with Large-Vessel Peripheral Arterial Disease Cholesterol lowering and mortality: the importance of considering initial level of risk Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study Atherosclerosis: inhibition of regression as therapeutic possibilities Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association Niacin: the evidence, clinical use, and future directions. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Lack of effect of lovastatin therapy on the parameters of whole-body cholesterol metabolism Coronary vein graft disease: pathogenesis and prevention Niacin: another look at an underutilized lipid-lowering medication By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. Lipid-lowering for peripheral arterial disease of the lower limb The benefits of niacin in atherosclerosis Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration G protein-coupled receptors for energy metabolites as new therapeutic targets Epidemiologic study of type 2 diabetes in Taiwan Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Treatment of diabetes: the effect on serum lipids and lipoproteins Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey Prevalence of self-reported hypercholesterolaemia and its relation to dietary habits, in Greek adults; a national nutrition & health survey Current, new and future treatments in dyslipidaemia and atherosclerosis Risk-sensitive therapeutic strategies for coronary artery disease: toward testing-driven therapy in stable angina patients with low-to-intermediate risk cardiac imaging results The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities Surrogate measures of atherosclerosis and implications for evaluating cardiovascular risk Consensus statement on management of dyslipidemia in Indian subjects Nicotinic acid: a new look at an old drug Dietary and pharmacologic management of cholesterol Lipids, atherosclerosis, and restenosis after percutaneous transluminal coronary angioplasty Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia Differential effects of nicotinic acid in subjects with different LDL subclass patterns Low level hyperlipidemia impairs endothelium-dependent relaxation of porcine coronary arteries by two mechanisms. Functional change in endothelium and impairment of endothelium-dependent relaxation by two mediators Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization Reducing Cholesterol Intake: Are the recommendations valid? Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial Fatty acid composition of the diet: impact on serum lipids and atherosclerosis Niacin or ezetimibe for patients with, or at risk of coronary heart disease Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia Clinical pharmacokinetics of pravastatin The clinical significance of serum high density lipoproteins

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software